Harmony Biosciences Holdings Inc (HRMY) Stock Price, Quote & News

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical tr...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 539 9800

Website: www.harmonybiosciences.com

Address:

630 West Germantown Pike, Suite 215, Plymouth Meeting, United States

Doozio Jul. 3 at 4:23 PM

Bahhh FRYday afterhours close is in $HRMY ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 5:28 PM

$XBI is ready to cause a LGNDary RCUS in RYTM n $HRMY n da MAC is back this July ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 3:22 PM

Da chop chop has da huckleberries as It’s all coming together in $HRMY ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 19 at 3:32 PM

Moar XBI 🎁s in $HRMY its gonna be LGNDary ONTO 🐒🍌🧠⏰♾️.

0 · Reply

2Little2Fast Jun. 18 at 2:16 PM

$HRMY is this going up again or not?

0 · Reply

Doozio Jun. 17 at 5:32 PM

Chop chop huckleberries as it all comes together in $HRMY ONTO 🐒🍌🧠⏰♾️

0 · Reply

2Little2Fast Jun. 15 at 2:10 PM

$HRMY BTD

0 · Reply

Invest2live Jun. 10 at 8:35 PM

$HRMY 24% already; congrats 🌟🌿🔆 Checkout $IONQ and $NICE

0 · Reply

SuperGreenToday Jun. 3 at 4:22 PM

$HRMY Share Price: $32.44 Contract Selected: Dec 18, 2026 $30 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.40 – $10.27 Potential Upside: 73% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Doozio May. 21 at 12:03 AM

If Roger starts rocking in $HRMY ???? $XBI gets $LGND ary ONTO 🐒🍌🧠⏰♾️

0 · Reply

Harmony Biosciences price target raised to $36 from $30 at Deutsche Bank

Jun 15, 2026, 10:53 AM EDT - 19 days ago

20 growth stocks priced as value stocks

ADMA AMG ANIP ARR BILL CG DAN

Jun 11, 2026, 8:05 AM EDT - 23 days ago

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Jun 9, 2026, 8:40 AM EDT - 25 days ago

Harmony Biosciences Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 27, 2026, 8:05 AM EDT - 5 weeks ago

Harmony Biosciences to Participate in Upcoming Investor Conferences

May 14, 2026, 4:00 PM EDT - 7 weeks ago

Harmony Biosciences Holdings Transcript: AGM 2026

2026-05-08T14:41:09.000Z - 2 months ago

Harmony Biosciences price target raised to $29 from $25 at Truist

2026-05-07T14:35:42.000Z - 2 months ago

Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B

May 7, 2026, 8:30 AM EDT - 2 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Harmony Biosciences Holdings Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Harmony Biosciences Holdings Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Harmony Biosciences Holdings Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Apr 23, 2026, 8:05 AM EDT - 2 months ago

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-22T15:04:39.000Z - 2 months ago

Harmony Biosciences price target raised to $72 from $62 at Oppenheimer

2026-04-21T16:53:45.000Z - 2 months ago

Harmony patent litigation update ‘major positive,’ says Mizuho

2026-04-21T16:49:54.000Z - 2 months ago

Harmony extends rally, shares up 16% after Mizuho research note

Apr 16, 2026, 8:05 AM EDT - 2 months ago

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

2026-04-14T12:45:45.000Z - 2 months ago

Harmony Biosciences appoints Reicin as Chief Financial Officer

Apr 14, 2026, 8:05 AM EDT - 2 months ago

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Apr 13, 2026, 9:30 AM EDT - 2 months ago

Harmony Biosciences Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Harmony Biosciences Holdings Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Harmony Biosciences Holdings Proxy statement: Proxy filing

2026-04-02T12:16:55.000Z - 3 months ago

Harmony Biosciences appoints Anastasiou as Chief Operating Officer

Apr 2, 2026, 8:05 AM EDT - 3 months ago

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Mar 31, 2026, 8:05 AM EDT - 3 months ago

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

2026-02-25T13:55:15.000Z - 4 months ago

Harmony Biosciences price target lowered to $30 from $31 at Deutsche Bank

2026-02-25T12:32:18.000Z - 4 months ago

Harmony Biosciences price target lowered to $36 from $46 at UBS

2026-02-24T21:05:37.000Z - 4 months ago

Harmony Biosciences price target lowered to $28 from $32 at BofA

Feb 24, 2026, 8:30 AM EST - 4 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 4 months ago

Harmony Biosciences Holdings Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 4 months ago

Harmony Biosciences Holdings Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 4 months ago

Harmony Biosciences Holdings Slides: Q4 2025

2026-02-24T12:44:01.000Z - 4 months ago

Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.01B

Feb 24, 2026, 7:30 AM EST - 4 months ago

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

2026-02-23T11:42:13.000Z - 4 months ago

Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank

Feb 17, 2026, 8:05 AM EST - 4 months ago

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Feb 10, 2026, 8:05 AM EST - 5 months ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 13, 2026, 7:30 PM EST - 6 months ago

Harmony Biosciences Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 6 months ago

Harmony Biosciences Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:05 AM EST - 6 months ago

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Jan 7, 2026, 8:05 AM EST - 6 months ago

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 6:30 AM EST - 7 months ago

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Dec 8, 2025, 8:05 AM EST - 7 months ago

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Dec 3, 2025, 10:30 AM EST - 7 months ago

Harmony Biosciences Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 2:35 PM EST - 7 months ago

Harmony Biosciences Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:05 AM EST - 7 months ago

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Nov 24, 2025, 8:05 AM EST - 7 months ago

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Nov 19, 2025, 8:05 AM EST - 8 months ago

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Nov 4, 2025, 8:30 AM EST - 8 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Harmony Biosciences Holdings Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Harmony Biosciences Holdings Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Harmony Biosciences Holdings Slides: Q3 2025

Nov 4, 2025, 7:30 AM EST - 8 months ago

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Oct 23, 2025, 8:05 AM EDT - 9 months ago

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Sep 24, 2025, 8:33 AM EDT - 10 months ago

Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

Sep 24, 2025, 8:00 AM EDT - 10 months ago

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Sep 15, 2025, 2:18 PM EDT - 10 months ago

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

AGYS ASTH CORT ENVA GSHD HASI KNTK

Sep 4, 2025, 2:10 PM EDT - 10 months ago

Harmony Biosciences Holdings Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:05 AM EDT - 11 months ago

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Aug 21, 2025, 8:05 AM EDT - 11 months ago

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Aug 5, 2025, 8:30 AM EDT - 11 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 11 months ago

Harmony Biosciences Holdings Quarterly report: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 11 months ago

Harmony Biosciences Holdings Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 11 months ago

Harmony Biosciences Holdings Slides: Q2 2025

Aug 5, 2025, 7:30 AM EDT - 11 months ago

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Jul 22, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 17, 2025, 10:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: H.C. Wainwright "HCW@Home" Series

Jul 15, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Jun 11, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Jun 9, 2025, 3:20 PM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Jun 4, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Slides: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance

May 6, 2025, 7:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Slides: Corporate Presentation

Apr 29, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Apr 9, 2025, 3:00 PM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Proxy statement: Proxy Filing

Apr 3, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Mar 26, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Doozio Jul. 3 at 4:23 PM

Bahhh FRYday afterhours close is in $HRMY ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 5:28 PM

$XBI is ready to cause a LGNDary RCUS in RYTM n $HRMY n da MAC is back this July ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 3:22 PM

Da chop chop has da huckleberries as It’s all coming together in $HRMY ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 19 at 3:32 PM

Moar XBI 🎁s in $HRMY its gonna be LGNDary ONTO 🐒🍌🧠⏰♾️.

0 · Reply

2Little2Fast Jun. 18 at 2:16 PM

$HRMY is this going up again or not?

0 · Reply

Doozio Jun. 17 at 5:32 PM

Chop chop huckleberries as it all comes together in $HRMY ONTO 🐒🍌🧠⏰♾️

0 · Reply

2Little2Fast Jun. 15 at 2:10 PM

$HRMY BTD

0 · Reply

Invest2live Jun. 10 at 8:35 PM

$HRMY 24% already; congrats 🌟🌿🔆 Checkout $IONQ and $NICE

0 · Reply

SuperGreenToday Jun. 3 at 4:22 PM

0 · Reply

Doozio May. 21 at 12:03 AM

If Roger starts rocking in $HRMY ???? $XBI gets $LGND ary ONTO 🐒🍌🧠⏰♾️

0 · Reply

Estimize May. 13 at 10:00 AM

Wall St is expecting 1.15 EPS for $HRMY Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co

0 · Reply

StocktwitsEarnings May. 7 at 12:24 PM

$HRMY Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.56 down -29.11% YoY • Reported revenue of $215.39M up 16.59% YoY

0 · Reply

MagicDiligence Apr. 27 at 11:07 AM

A lot of biotech names screen cheap right before the story falls apart. $HRMY is interesting because it does not seem to have the usual problems. MagicDiligence currently gives Harmony Biosciences a clean pass based on WAKIX durability, balance sheet strength, and a surprisingly clean risk profile. https://magicdiligence.com/articles/harmony-biosciences-hrmy-a-clean-pass

0 · Reply

RunnerSignals Apr. 21 at 8:32 PM

market warriors $HRMY $RCUS $ANNA $BNTX $REI flipped red to green HRMY 5.8x vol and RCUS 3.3x show real accumulation, BNTX solid follow-through; REI ANNA lighter suggest mixed short covering

0 · Reply

mikesterz7 Apr. 21 at 6:24 PM

$HRMY Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

0 · Reply

StocktwitsNews Apr. 21 at 5:27 PM

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? $HRMY $IJR $IWM https://stocktwits.com/news/equity/markets/hrmy-stock-best-intraday-gains-18-months-what-mizuho-analysts-said/cZBIYK9RI69

0 · Reply

notreload_ai Apr. 21 at 5:03 PM

$HRMY wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target. https://notreload.xyz/xy/mizuho-harmony-wakix-protected-until-2030-after-lawsuit/

0 · Reply

outlawinvestor1 Apr. 21 at 4:29 PM

$HRMY Mizuho analyst Graig Suvannavejh says the firm has learned of a new patent lawsuit filed by Harmony Biosciences against AET Pharma, the sole remaining generic challenger that has yet to settle. Harmony's new lawsuit alleges infringement of a patent covering an amorphous formulation of pitolisant, which was recently licensed by Harmony, the analyst tells investors in a research note. Mizuho now believes Harmony's Wakix franchise should be viewed as "protected and fully intact" until 2030. The firm views the lawsuit as a "significant development" and "major positive" for the company. It should help remove a "major stock overhang" stemming from concerns around a generic coming well before 2030, contends Mizuho. The firm reiterates a an Outperform rating on the shares with a $50 price target.

0 · Reply

outlawinvestor1 Apr. 21 at 4:27 PM

$HRMY looking for news, but can't find any. leak?

0 · Reply

nikeita Apr. 20 at 12:36 PM

$NVAX I’m really curious to know whether John Jacobs was just as quiet when he was CEO of $HRMY. Anyone?

1 · Reply

DavoleBomb Apr. 10 at 3:11 PM

$HRMY Risk/reward looking good at this level, I'm in.

0 · Reply

SportTrade Apr. 6 at 10:57 AM

$PTN $HRMY $SLNO $RYTM $AARD Neurocrine is (reportedly) in advanced talks to acquire Soleno for more than $2.5 billion, which—if true—would validate the value of the PWS market and the scarcity of remaining public PWS assets. Expect investors to start doing more diligence on rare obesity companies.

0 · Reply

Market Cap	2.16B
Revenue (ttm)	868.45M
Net Income (ttm)	158.69M
EPS (ttm)	N/A
PE Ratio	14.52
Forward PE	11.05
Profit Margin	18.27%
Debt to Equity Ratio	0.17

Volume	1,012,900
Avg Vol	828,576
Day's Range	N/A - N/A
Shares Out	57.89M
Stochastic %K	97%
Beta	0.94
Analysts	Sell
Price Target	$44.33